Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nelfinavir

C M Perry1, P Benfield

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Nelfinavir, an HIV-1 protease inhibitor, effectively reduces viral load, especially in combination therapy. Food intake enhances nelfinavir absorption, improving its efficacy in HIV patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to: Moclobemide: An update of its pharmacological properties and therapeutic use.

Drugs·2017
Same author

Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

CNS drugs·2016
Same author

Erratum to: Pergolide: a review of its pharmacology and therapeutic use in Parkinson's disease.

CNS drugs·2016
Same author

Trastuzumab.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Interferon-beta-1a: A Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Recombinant Mammalian Cell-Derived Somatropin: A Review of its Pharmacological Properties and Therapeutic Potential in the Management of Wasting Associated with HIV Infection.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Pharmacology
  • Virology
  • Immunology

Background:

  • Nelfinavir is a protease inhibitor with demonstrated activity against HIV-1.
  • HIV-1 resistance patterns to nelfinavir differ from other protease inhibitors.
  • Nelfinavir's pharmacokinetic profile is influenced by food intake.

Purpose of the Study:

  • To evaluate the efficacy of nelfinavir in reducing HIV RNA levels.
  • To assess the impact of food on nelfinavir's plasma concentration.
  • To investigate nelfinavir's effectiveness in combination therapy for HIV-1 infection.

Main Methods:

  • Administration of single 400 and 800mg doses of nelfinavir with and without food in healthy volunteers.
  • Treatment of HIV-1 patients with various nelfinavir monotherapy and combination regimens.

Related Experiment Videos

  • Monitoring of plasma HIV RNA levels and CD4+ cell counts.

    • Main Results:

    • Nelfinavir administration with food increased plasma concentration-time AUC values by 27-50% compared to fasted state.
    • Reductions in plasma HIV RNA to undetectable levels were observed with nelfinavir monotherapy.
    • Combination therapy with nelfinavir and stavudine showed greater HIV RNA reduction and CD4+ cell increase than stavudine monotherapy.
    • A triple regimen including nelfinavir, zidovudine, and lamivudine led to undetectable HIV RNA in 11 of 12 patients with early HIV infection.

    Conclusions:

    • Nelfinavir absorption is enhanced by food, potentially improving its therapeutic effect.
    • Nelfinavir demonstrates efficacy in reducing viral load, both as monotherapy and in combination regimens.
    • Combination therapy involving nelfinavir offers significant benefits in managing HIV-1 infection, including improved viral suppression and immune reconstitution.